1.925USD-10.05%Mkt Cap: 85.74M USDP/E: —Last update: 2026-06-01
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The com…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap85.74M USD
Enterprise Value89.68M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-28.75M USD
Revenue/Share—
Last Price1.925 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-20.38
PEG—
EV/EBITDA-2.69
EV/Revenue—
P/S—
P/B-7.75
EPS (TTM)-1.07
EPS (Forward)-0.10
52W Range
1.15055% of range2.570
52W High2.570 USD
52W Low1.150 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE471.71%
ROA-420.41%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.24M USD
CapEx (TTM)466.42K USD
FCF Margin—
FCF Yield-1.68%
Net Debt425.39K USD
Net Debt/EBITDA-0.01
Balance Sheet
Debt/Equity—
Current Ratio0.05
Quick Ratio0.05
Book Value/Sh-0.2760 USD
Cash/Share0.0210 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)9.398 USD
Target Range6.000 USD – 13.00 USD
# Analysts4
Ownership
Shares Out.44.54M
Float36.21M
Insiders22.14%
Institutions6.53%
Short Interest
Short Ratio1.7d
Short % Float3.19%
Short % Out.2.95%
Shares Short1.32M
Short (prev mo.)1.39M
Technical
SMA 501.562 (+23.2%)
SMA 2001.711 (+12.5%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)839.30K
Avg Vol (10d)858.11K
Technical Indicators
RSI (14)72.0
MACD0.1077
MACD Signal0.0869
MACD Hist.+0.0208
BB Upper2.036 USD
BB Middle1.786 USD
BB Lower1.535 USD
BB Width28.00%
ATR (14)0.1402 USD
Vol Ratio (20d)1.97x